LILRB1 and neoplasm: Current studies have shown that the inhibition of the LILRB1 protein with the simultaneous administration of anti-CD47 monoclonal antibodies can significantly increase the phagocytosis and kill capacity of macrophages on tumor cells (Figure 3B), and the inhibition of LILRB1 does not damage normal tissue cells in vivo.